Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
作者信息
Patel Viralkumar, Keating Michael J, Wierda William G, Gandhi Varsha
机构信息
a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
出版信息
Leuk Lymphoma. 2016;57(6):1494-7. doi: 10.3109/10428194.2015.1102243. Epub 2015 Nov 16.
Abstract
摘要
相似文献
1
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.AXL抑制剂TP-0903、procaspase激活化合物B-PAC-1与伊布替尼在慢性淋巴细胞白血病中的临床前联合应用。
Leuk Lymphoma. 2016;57(6):1494-7. doi: 10.3109/10428194.2015.1102243. Epub 2015 Nov 16.
2
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.靶向Axl抑制使慢性淋巴细胞白血病B细胞易于凋亡，并与BTK抑制剂联合使用时显示出协同/相加效应。
Clin Cancer Res. 2015 May 1;21(9):2115-26. doi: 10.1158/1078-0432.CCR-14-1892. Epub 2015 Feb 11.
3
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.依鲁替尼和idelalisib协同靶向套细胞淋巴瘤和慢性淋巴细胞白血病中由BCR控制的黏附：联合治疗的理论依据。
Blood. 2015 Apr 2;125(14):2306-9. doi: 10.1182/blood-2014-12-619163.
4
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对布鲁顿酪氨酸激酶（BTK）抑制剂耐药的机制
Clin Adv Hematol Oncol. 2021 Jul;19(7):436-438.
5
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.布鲁顿激酶抑制剂在慢性淋巴细胞白血病中的应用
Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342.
6
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.接受依鲁替尼治疗的慢性淋巴细胞白血病患者中Toll样受体的二分反应
Leukemia. 2019 Apr;33(4):1030-1051. doi: 10.1038/s41375-018-0335-2. Epub 2019 Jan 3.
7
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.低MITF/AXL比值预示黑色素瘤对多种靶向药物的早期耐药性。
Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.
8
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.新型受体酪氨酸激酶 Axl 在 B 细胞慢性淋巴细胞白血病中持续激活，并作为非受体激酶的停靠点发挥作用：对治疗的影响。
Blood. 2011 Feb 10;117(6):1928-37. doi: 10.1182/blood-2010-09-305649. Epub 2010 Dec 6.
9
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.靶向CD38增强依鲁替尼在慢性淋巴细胞白血病中的抗白血病活性。
Clin Cancer Res. 2019 Jul 1;25(13):3974-3985. doi: 10.1158/1078-0432.CCR-18-3412. Epub 2019 Apr 2.
10
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.依鲁替尼与MDM-2抑制剂协同作用，促进B细胞慢性淋巴细胞白血病的细胞毒性。
Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.
引用本文的文献
1
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.AXL通过调节免疫抑制性巨噬细胞极化促进炎性乳腺癌进展。
Breast Cancer Res. 2025 May 6;27(1):70. doi: 10.1186/s13058-025-02015-8.
2
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.AXL作为急性髓系白血病中的免疫调节因子和治疗靶点：从当前进展到新策略
Exp Hematol Oncol. 2024 Oct 4;13(1):99. doi: 10.1186/s40164-024-00566-8.
3
Drugging the efferocytosis process: concepts and opportunities.药物干预细胞吞噬作用的过程：概念与机遇
Nat Rev Drug Discov. 2022 Aug;21(8):601-620. doi: 10.1038/s41573-022-00470-y. Epub 2022 Jun 1.
4
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.AXL抑制剂在肺癌治疗中的发展：最新进展与挑战
Front Oncol. 2022 Mar 3;12:811247. doi: 10.3389/fonc.2022.811247. eCollection 2022.
5
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.Gas6/Axl 信号通路在癌症治疗中的靶向作用。
Int J Mol Sci. 2021 Sep 15;22(18):9953. doi: 10.3390/ijms22189953.
6
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.MERTK 在癌症治疗中的作用：靶向肿瘤细胞和免疫系统中的受体酪氨酸激酶。
Pharmacol Ther. 2020 Sep;213:107577. doi: 10.1016/j.pharmthera.2020.107577. Epub 2020 May 14.
7
AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.AXL受体酪氨酸激酶作为血液系统恶性肿瘤的治疗靶点：聚焦于多发性骨髓瘤
Cancers (Basel). 2019 Nov 5;11(11):1727. doi: 10.3390/cancers11111727.
8
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.AXL 受体酪氨酸激酶作为一种有前途的抗癌方法：功能、分子机制和临床应用。
Mol Cancer. 2019 Nov 4;18(1):153. doi: 10.1186/s12943-019-1090-3.
9
Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.来自接受依鲁替尼治疗患者的慢性淋巴细胞白血病细胞对Axl受体酪氨酸激酶抑制剂疗法敏感。
Oncotarget. 2018 Dec 14;9(98):37173-37184. doi: 10.18632/oncotarget.26444.
10
Role of Bruton's tyrosine kinase in B cells and malignancies.布鲁顿酪氨酸激酶在 B 细胞及恶性肿瘤中的作用。
Mol Cancer. 2018 Feb 19;17(1):57. doi: 10.1186/s12943-018-0779-z.
本文引用的文献
1
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.慢性淋巴细胞白血病患者对 BTK 抑制产生耐药性后的克隆进化。
Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.
2
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.剪接调节剂苏地霉素可诱导特异性抗肿瘤反应，并在慢性淋巴细胞白血病中与依鲁替尼协同作用。
Oncotarget. 2015 Sep 8;6(26):22734-49. doi: 10.18632/oncotarget.4212.
3
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.塞利尼索对依鲁替尼获得性耐药有效，并在慢性淋巴细胞白血病中与依鲁替尼协同作用。
Blood. 2015 May 14;125(20):3128-32. doi: 10.1182/blood-2015-01-621391. Epub 2015 Apr 2.
4
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.药理学和蛋白质分析表明，维奈托克（ABT-199）是慢性淋巴细胞白血病中与伊布替尼联用的最佳搭档。
Clin Cancer Res. 2015 Aug 15;21(16):3705-15. doi: 10.1158/1078-0432.CCR-14-2809. Epub 2015 Mar 31.
5
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.靶向Axl抑制使慢性淋巴细胞白血病B细胞易于凋亡，并与BTK抑制剂联合使用时显示出协同/相加效应。
Clin Cancer Res. 2015 May 1;21(9):2115-26. doi: 10.1158/1078-0432.CCR-14-1892. Epub 2015 Feb 11.
6
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.蛋白酶体抑制剂卡非佐米可增强依鲁替尼在慢性淋巴细胞白血病中的作用。
Blood. 2015 Jan 8;125(2):407-10. doi: 10.1182/blood-2014-07-585364.
7
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.凋亡执行蛋白酶在慢性淋巴细胞白血病细胞中的表达及其被一种蛋白酶原激活化合物激活的情况。
Blood. 2015 Feb 12;125(7):1126-36. doi: 10.1182/blood-2014-01-546796. Epub 2014 Dec 23.
8
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
9
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.伊布替尼治疗期间持续的淋巴细胞增多与独特的分子特征相关，并不表明对治疗的反应不佳。
Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10.
10
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.肿瘤抑制轴p53/miR-34a调节B细胞慢性淋巴细胞白血病中的Axl表达：对p53缺陷型慢性淋巴细胞白血病患者治疗的意义。
Leukemia. 2014 Feb;28(2):451-5. doi: 10.1038/leu.2013.298. Epub 2013 Oct 18.
Zotero 插件